Business Wire

Alvotech Bondholders Convert More Than $100m at Pre-Money Valuation of $2.7bn

Share

Alvotech Holdings SA today announced that it has entered into an amendment and restatement agreement with bondholders of its $300m covertible bond issued on December 14, 2018. Bondholders have exercised their conversion rights on approximately one quarter of the value of the bond, converting $106m of principal and accrued interest into equity at an exercise price that gives the company a pre-money valuation of $2.7bn.

The company and bondholders also agreed to improve terms on the remaining bond and extend its maturity to 2025, thereby decreasing the company's cost of capital and freeing resources to apply to the execution of its business strategy. Further terms were amended to add additional capital to the company.

Robert Wessman, Chairman of Alvotech commented: “With this transaction our stakeholders have reiterated their longstanding confidence in and commitment to our mission: to increase access to the highest quality biologics medicines for patients around the world.”

In November of 2020, the U.S. Food and Drug Administration and European Medicines Agency accepted Alvotech’s regulatory submissions for AVT02, a candidate interchangeable biosimilar to AbbVie’s Humira®. A decision from the FDA regarding the company’s Biologics License Application (BLA) for AVT02 is expected in September of 2021 and an EMA decision for the AVT02 European Marketing Authorization Application (MAA) is anticipated in the fourth quarter of 2021.

In May 2021, Alvotech USA Inc. filed a lawsuit in the Eastern District of Virginia seeking to invalidate four of AbbVie’s key patents. The lawsuit also argues that AbbVie’s patent strategy, which has been under recent Congressional scrutiny, renders its Humira® patents unenforceable. Further, the lawsuit points out that AbbVie has failed to sue Alvotech’s US affiliate (the actual BLA applicant) at all. At stake are billions of dollars of cost to the US healthcare system, negatively impacting consumers and taxpayers.

In June of 2021, Alvotech’s switching study for AVT02 reached primary completion. Alvotech is the only known company that has both developed a biosimilar candidate for the high-concentration Humira® and is executing a switching study to support approval as an interchangeable product. Top-line results from the switching study are expected later this year.

About Alvotech:

Alvotech is a multinational biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets. We are specialists in biotechnology, seeking to be a global leader in the biosimilar space by delivering high quality, cost-competitive products and services to our partners and to patients worldwide. Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar products. Alvotech’s shareholder base includes, among others, Aztiq Pharma, led by founder and Chairman Mr. Robert Wessman, Fuji Pharma from Japan, YAS Holdings form Abu Dhabi, Shinhan from Korea, Baxter Healthcare SA from the US, ATHOS (Strüngmann Family Office) from Germany and CVC Capital Partners and Temasek from Singapore through their participation in Alvogen.

Alvotech‘s initial pipeline contains several monoclonal-antibody and fusion-protein biosimilar candidates aimed at treating autoimmunity, oncology and inflammatory conditions to improve quality of life for patients around the world. For more information, please visit our website, www.alvotech.com or follow us on LinkedIn, Twitter and Facebook.

Forward Looking Statement

Except for historical information contained herein, the matters set forth in this press release are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are not based on historical facts but rather on our expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities. Statements in this press release about our future plans and intentions, results, level of activities, performance, goals or achievements or other future events constitute forward looking statements. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements. Any of the assumptions underlying forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in forward-looking statements may not actually be achieved. Nothing contained in this press release of them should be construed as a profit forecast or profit estimate. Wherever possible, words such as “anticipate”, “believe”, “expect”, “may”, “could”, “will”, “potential”, “intend”, “estimate”, “should”, “plan”, “predict”, or the negative or other variations of statements reflect management’s current beliefs and assumptions and are based on the information currently available to our management. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Corporate Communications
Elisabet Hjaltadottir
E-mail: Alvotech.media@alvotech.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Intelligent Fingerprinting’s Simple Saliva-based COVID-19 Test Now CE Marked and Available for Sale25.10.2021 09:16:00 CEST | Press release

Intelligent Fingerprinting has announced that its saliva-based COVID-19 test now carries CE marking and is available for sale. The new VSS-GP COVID-19 Saliva Test uses a simple swab to collect saliva from just inside the cheek, providing a much easier alternative to current throat and nose tests that can cause gagging, sneezing or distress during sample collection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005324/en/ The new VSS-GP COVID-19 Saliva Test from Intelligent Fingerprinting uses a simple swab to collect saliva from just inside the cheek, providing a much easier alternative to current throat and nose tests that can cause gagging, sneezing or distress during sample collection. (Photo: Business Wire) Easier, more comfortable COVID-19 testing Intelligent Fingerprinting’s reliable and easy-to-use saliva-based lateral flow test supports frequent COVID-19 testing for applications including schools, workplaces,

iBASIS Wins Best Global Wholesale Carrier – Voice at the Global Carrier Awards 202125.10.2021 08:00:00 CEST | Press release

iBASIS, the leading provider of communications solutions for operators and digital players worldwide, won Best Wholesale Global Carrier – Voice 2021 at the 17th edition of the Global Carrier Awards (GCAs) held during Capacity Europe in London, U.K. Commending the greatest accomplishments in telecom, tech, and ICT space, the win recognizes iBASIS’ transformation under the leadership of Alexandre Pébereau, its Chief Executive Officer. In 2019, Pébereau also received the GCA for Best Strategic Acquisition of SFR ICS from the Altice Group and iBASIS from Royal KPN. The company received four additional Global Carrier Awards, including Best Strategic Acquisition of NOS International Carrier Services (NOS ICS) in 2020. “It is remarkable that iBASIS is being recognized as it celebrates the 25th anniversary of its launch of VoIP. Then, live calls on the Internet seemed impossible. Today, the transformation of Tier 1 voice services depend on the very same platform,” comments Pébereau. “This win

EIG Signs Agreement to Acquire 10% Interest in APLNG for US$1.592 Billion24.10.2021 23:30:00 CEST | Press release

EIG, a leading institutional investor to the global energy and infrastructure sectors, today announced that it has entered into a definitive agreement under which it will acquire a 10% interest in Australia Pacific LNG Pty Limited (“APLNG” or the “Project”) from Origin Energy Limited (“Origin”) for an equity purchase price of $1.592 billion. This innovative agreement represents the first ever acquisition of an interest in an operational integrated LNG project by a private equity sponsor. Asset Highlights and Strategic Rationale A tier-one, integrated LNG project with an established liquefaction facility, APLNG is the largest LNG project by liquefaction capacity on Australia’s eastern seaboard and a major supplier of LNG to Asia and gas to Australia’s domestic market. The Project, which is located in Gladstone, Queensland, has a track record of consistently achieving its nameplate capacity of 9.0 Mtpa and holds a leading acreage position spanning the prolific Surat and Bowen basins, pro

SES-17 Successfully Launched on Ariane 524.10.2021 06:08:00 CEST | Press release

SES announced today that the SES-17 satellite was successfully launched into space onboard an Ariane 5 launcher operated by Arianespace from the Europe’s Spaceport in Kourou, French Guiana at 11:10 pm local time (02:10 am UTC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211023005019/en/ SES-17 Successfully Launched on Ariane 5 (Photo: Business Wire) The multi-mission Ka-band satellite will provide comprehensive coverage across the Americas, the Caribbean and the Atlantic Ocean. From its orbital slot of 67.1 degrees West orbital slot, the very high throughput geostationary (GEO) satellite incorporating cutting-edge technologies is set to deliver the best connectivity experience for SES customers operating in the aeronautical, maritime, enterprise, and government markets. Built by Thales Alenia Space, SES-17 marks an important milestone in satellite technology as the first Ka-band geostationary satellite to embark a fully

Peru Holds a Ribbon Cutting Ceremony at Its Pavilion at Dubai Expo and Wins 4 World Travel Awards22.10.2021 19:15:00 CEST | Press release

The Dubai World Expo took place in an electrifying musical atmosphere where thousands of attendees were captivated by the variety of artistic, musical and cultural expressions that characterize the different regions of Peru. All this was part of the inauguration of the Peru Pavilion at the most important cultural event in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211022005454/en/ Peru inaugurated its Pavilion at Expo 2020 Dubai and received four awards from the “Tourism Oscars.” (Photo: Business Wire) The Peru Pavilion was inaugurated by the Commissioner General for Peru at the Expo, Amora Carbajal, and Najeeb Mohammed Al-Ali, Executive Director of Expo 2020 Dubai, in front of official representatives from different country pavilions. “The purpose of the pavilion is to offer a complete learning experience about ancient Peruvian wisdom throughout the visit, communicating the importance of the heritage, biodive

Schlumberger Announces Third-Quarter 2021 Results22.10.2021 12:50:00 CEST | Press release

Schlumberger Limited (NYSE: SLB) today reported results for the third-quarter 2021. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2021Jun. 30, 2021Sept. 30, 2020SequentialYear-on-yearRevenue* $5,847 $5,634 $5,258 4% 11% Income (loss) before taxes - GAAP basis $691 $542 $(54) 28% n/m Net income (loss) - GAAP basis $550 $431 $(82) 28% n/m Diluted EPS (loss per share) - GAAP basis $0.39 $0.30 $(0.06) 30% n/m Adjusted EBITDA** $1,296 $1,198 $1,018 8% 27% Adjusted EBITDA margin** 22.2% 21.3% 19.4% 90 bps 280 bps Pretax segment operating income** $908 $807 $575 12% 58% Pretax segment operating margin** 15.5% 14.3% 10.9% 120 bps 460 bps Net income, excluding charges & credits** $514 $431 $228 19% 126% Diluted EPS, excluding charges & credits** $0.36 $0.30 $0.16 20% 125% Revenue by Geography International $4,675 $4,511 $4,210 4% 11% North America* 1,129 1,083 1,034 4% 9% Other 43 40 14 n/m n/m $5,847 $5,634 $5,258 4% 11% *Schlumberger dive

Disruptive.Asia: Huawei's Ryan Ding and Peng Song Discuss How Operators Can Leverage Connectivity to Unlock New Growth22.10.2021 12:30:00 CEST | Press release

Disruptive.Asia reported that Ryan Ding and Peng Song stressed the growing importance of connectivity in driving industry growth and generating value amid a rapidly evolving landscape at the 7th Ultra-Broadband Forum (UBBF 2021) in Dubai, which is jointly hosted by the UN Broadband Commission and Huawei. Ding, Executive Director of the Board and President of the Carrier Business Group, Huawei, said that connectivity has made it possible to innovate, especially in a digital age where increasing efficiency has become paramount. The pandemic has also ushered a paradigm shift in connectivity, as homes turned into multi-functional centers for education, work, and business. It became increasingly clear that connectivity not only drives digital economies forward but also maintains the functioning of society. Peng, President of the Global Carrier Marketing & Solution Sales Department, Huawei, said that looking at connectivity through Huawei's C.A.F (Coverage, Architecture and Fusion) model can

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom